Digital PCR for EGFR T790M and C797S: Tracking Sequential Resistance After TKI Therapy

Overview

Resistance to EGFR-directed therapy tends to arrive in a predictable order, and this assay is built around that sequence. T790M classically emerges under earlier-generation inhibitor pressure, while C797S appears after a third-generation agent has been deployed against T790M. Targeting both substitutions in one highly sensitive reaction turns a vague clinical impression of progression into a named escape mechanism.

How It Works

Digital PCR splits a single prepared sample across many thousands of independent partitions before amplification begins. Each partition either contains a target molecule or does not, so after cycling the instrument counts positive compartments and applies Poisson statistics to derive an absolute molecule count without reference to a standard curve. Allele-specific probes distinguish the mutant sequence from abundant wild-type background. That partitioning is what allows a rare resistance allele to be called against overwhelming normal DNA, which matters because escape clones frequently represent a small fraction of circulating material at the moment progression becomes clinically visible.

Indications

The assay suits patients progressing on EGFR-directed treatment where the mechanism of escape must be named before the next line is chosen. Plasma is the usual matrix when re-biopsy is impractical, and tissue can be used where a fresh sample is obtainable. It also supports serial sampling across treatment, since an absolute count permits comparison between draws rather than a single snapshot. A negative plasma result does not exclude resistance, because shedding varies, so tissue confirmation remains appropriate when the clinical picture disagrees.

Specifications and Reporting

Confirm the blood volume required, the detection limit expressed as a mutant allele fraction, and the number of DNA copies interrogated per reaction, as a low input silently degrades sensitivity. Reports should give absolute mutant and wild-type counts alongside the fraction, name each substitution separately, and record whether input fell below the validated threshold.

Storage and Sourcing

Plasma work is governed by the clock. Blood drawn into standard EDTA tubes must reach separation within a short defined window, held at 2-8°C in transit, since leukocyte breakdown floods the sample with wild-type DNA and buries the signal. Cell-stabilising tubes extend that window and are worth their premium across dispersed collection networks. Separated plasma is archived frozen. Written courier schedules and documented draw-to-separation intervals matter more here than for any tissue-based test.

FAQ

Q: Why choose digital PCR over a broad sequencing panel when resistance is suspected? When the question is whether one known substitution is present, partition counting reaches a lower detection limit and returns faster than broad sequencing. Choose a wide panel instead when the escape route is genuinely unknown.

Q: What does a C797S finding imply for the next line of therapy? It indicates escape has occurred at the binding site targeted by third-generation inhibitors, so continuing the same agent is unlikely to help. The result should be discussed against current treatment guidance rather than treated as prescribing instruction.

Q: How fast must plasma reach the laboratory to keep circulating DNA usable? With standard EDTA collection the draw-to-separation interval is measured in hours, not days. Confirm the provider's stated window and validate your courier against it before committing collection sites to the workflow.